Clinical Trials Logo
  1. Home
  2. Unilateral Retinoblastoma
  3. NCT03932786

Studying Health Outcomes After Treatment in Patients With Retinoblastoma — RIVERBOAT  

Cancer Survivor Clinical Trial

Official title:
Research Into Visual Endpoints and RB Health Outcomes After Treatment (RIVERBOAT)

Clinical Trial Summary

This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma

Clinical Trial Description

PRIMARY OBJECTIVES: I. Define acute toxicity, subsequent malignant neoplasm (SMN) risk and visual outcomes in retinoblastoma (RB) survivors and compare patient centered psychosocial and neurocognitive and physical outcomes in survivors with normative data and sibling controls. II. Create the first Clinically-Annotated Patient Tissues to Analyze Gene INteractions to assess biologic correlates of disease and facilitate future research: The RIVERBOAT-CAPTAIN biorepository, including germline deoxyribonucleic acid (DNA) and tumor tissue from patients, with detailed patient, disease and treatment-related information. III. Using the RIVERBOAT-CAPTAIN clinically-annotated biorepository, determine the interplay between specific RB1 mutation type and the role of additional modifier genes in determining those tumor phenotypes that drive treatment decisions. OUTLINE: Patients are assigned to 1 of 2 cohorts. RETROSPECTIVE COHORT: Patients treated between 2008-2018 undergo collection of saliva samples at >= 6 months after treatment, and undergo vision assessment at >= 6 months after treatment and again 1 year later if necessary. Previously collected tissue samples at the time of surgery are also obtained. Patients also complete questionnaires at >= 6 months after treatment and again 2 years later. PROSPECTIVE COHORT: Patients treated between 2018-2023 undergo collection of saliva samples at the time of enrollment and at 6 months after treatment. Patients also undergo vision assessment at the time of enrollment, at 6 months, and 18 months after completion of treatment. Patients also complete questionnaires at 6 months and again 2 years later, as well as undergo collection of tissue samples at the time of surgery. Immediate family members with history of RB or RB1 gene mutation also undergo collection saliva samples. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03932786
Study type Observational
Source Vanderbilt-Ingram Cancer Center
Contact Vanderbilt-Ingram Service for Timely Access
Phone 800-811-8480
Email cip@vanderbilt.edu
Status Recruiting
Phase
Start date January 24, 2019
Completion date January 2031
View Details
See also
  Status Clinical Trial Phase
Completed NCT02235051 - Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors N/A
Completed NCT01439945 - Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer Phase 2
Active, not recruiting NCT02194387 - Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members N/A
Completed NCT01641068 - Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms N/A
Not yet recruiting NCT05403671 - Fit for Everyday Life - Increasing Exercise and Physical Activity in Those Rehablilitating From Cancer N/A
Completed NCT00246818 - Effect of Tai Chi Vs. Structured Exercise on Physical Fitness and Stress in Cancer Survivors Phase 2
Completed NCT02559557 - Culturally Adapted Parenting Intervention for Spanish-Speaking Parents in Improving Outcomes of Younger Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Survivors at Risk for Late Neurocognitive Effects N/A
Completed NCT00956475 - Quality of Life in Younger Leukemia and Lymphoma Survivors Phase 1
Completed NCT02032121 - Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors N/A
Completed NCT00932997 - Survivorship Booklets With or Without Individual Telephone Sessions in Increasing Knowledge About the Impact of Breast Cancer in African American and Latina Breast Cancer Survivors N/A
Completed NCT02566408 - Attitudes, Beliefs, and Preferences of Older Stage I-III Breast Cancer Survivors Towards Physical Activity N/A
Completed NCT02985411 - Harvest for Health in Older Cancer Survivors N/A
Completed NCT00915889 - Psychosocial Support for African-American, Latina-American, or European-American Cervical Cancer Survivors N/A
Completed NCT02518308 - Mindfulness Intervention in Reducing Anxiety in Patients Who Have Been Treated for Gynecologic Cancer N/A
Completed NCT03307044 - Fractional CO2 Laser Therapy for Survivors of Breast Malignancies N/A
Terminated NCT03781778 - Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors Phase 2
Completed NCT03520283 - Systems Support Mapping in Guiding Self-Management in Stage I-III Colorectal Cancer Survivors N/A
Completed NCT02662335 - Computerized Cognitive Retraining in Improving Cognitive Function in Breast Cancer Survivors N/A
Active, not recruiting NCT01347970 - Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF): A Phase IIB Randomized Placebo-Controlled Trial Phase 2
Completed NCT00713505 - Educational and Skills Training Program for Parents of Childhood Cancer Survivors Who Have Neurobehavioral Dysfunction N/A